中国实验血液学杂志
中國實驗血液學雜誌
중국실험혈액학잡지
JOURNAL OF EXPERIMENTAL HEMATOLOGY
2012年
3期
667-670
,共4页
辛春红%徐俊卿%隋晶蕊%王笑蕾
辛春紅%徐俊卿%隋晶蕊%王笑蕾
신춘홍%서준경%수정예%왕소뢰
真性红细胞增多症%血栓形成%栓塞
真性紅細胞增多癥%血栓形成%栓塞
진성홍세포증다증%혈전형성%전새
polycythemia vera%thrombosis%embolism
本研究分析真性红细胞增多症(PV)的临床特点、实验室检查结果、治疗及预后.对2001年1月至2011年7月在本院住院的71例(男性37例,女性34例,平均发病年龄57.8岁)PV患者的临床特点、染色体核型检查、BCR/ABL和JAK2V617F基因检查、血清乳酸脱氢酶(LDH)和神经元特异性烯醇酶(NSE)水平检测等方面进行了回顾性分析.结果表明,71例中血栓形成、栓塞34例(47.89%),出血10例(14.08%),脾大44例(61.97%),肝大12例(16.90%),起病隐匿,诊治其他疾病时发现者占18.31%,初诊时平均血红蛋白206.31 g/L.67例PV患者染色体核型检查显示4例(5.97%)染色体核型异常.38例患者JAK2V617F基因检查显示31例JAK2V617F基因阳性(81.58%).血清LDH与NSE平均水平高于正常值,且均与血红蛋白呈正相关(P=0.007,P=0.005).3例进展为骨髓纤维化,1例脑出血死亡,1例患者转化为ANLL-M2,经化疗无效后死亡.结论:PV是以血栓及出血为主要并发症的骨髓增殖性肿瘤,起病隐匿,血清LDH与NSE水平高于正常值,推断血清LDH与NSE水平可反映PV患者骨髓造血细胞的恶性增殖程度并可作为判定PV的疗效指标之一.
本研究分析真性紅細胞增多癥(PV)的臨床特點、實驗室檢查結果、治療及預後.對2001年1月至2011年7月在本院住院的71例(男性37例,女性34例,平均髮病年齡57.8歲)PV患者的臨床特點、染色體覈型檢查、BCR/ABL和JAK2V617F基因檢查、血清乳痠脫氫酶(LDH)和神經元特異性烯醇酶(NSE)水平檢測等方麵進行瞭迴顧性分析.結果錶明,71例中血栓形成、栓塞34例(47.89%),齣血10例(14.08%),脾大44例(61.97%),肝大12例(16.90%),起病隱匿,診治其他疾病時髮現者佔18.31%,初診時平均血紅蛋白206.31 g/L.67例PV患者染色體覈型檢查顯示4例(5.97%)染色體覈型異常.38例患者JAK2V617F基因檢查顯示31例JAK2V617F基因暘性(81.58%).血清LDH與NSE平均水平高于正常值,且均與血紅蛋白呈正相關(P=0.007,P=0.005).3例進展為骨髓纖維化,1例腦齣血死亡,1例患者轉化為ANLL-M2,經化療無效後死亡.結論:PV是以血栓及齣血為主要併髮癥的骨髓增殖性腫瘤,起病隱匿,血清LDH與NSE水平高于正常值,推斷血清LDH與NSE水平可反映PV患者骨髓造血細胞的噁性增殖程度併可作為判定PV的療效指標之一.
본연구분석진성홍세포증다증(PV)적림상특점、실험실검사결과、치료급예후.대2001년1월지2011년7월재본원주원적71례(남성37례,녀성34례,평균발병년령57.8세)PV환자적림상특점、염색체핵형검사、BCR/ABL화JAK2V617F기인검사、혈청유산탈경매(LDH)화신경원특이성희순매(NSE)수평검측등방면진행료회고성분석.결과표명,71례중혈전형성、전새34례(47.89%),출혈10례(14.08%),비대44례(61.97%),간대12례(16.90%),기병은닉,진치기타질병시발현자점18.31%,초진시평균혈홍단백206.31 g/L.67례PV환자염색체핵형검사현시4례(5.97%)염색체핵형이상.38례환자JAK2V617F기인검사현시31례JAK2V617F기인양성(81.58%).혈청LDH여NSE평균수평고우정상치,차균여혈홍단백정정상관(P=0.007,P=0.005).3례진전위골수섬유화,1례뇌출혈사망,1례환자전화위ANLL-M2,경화료무효후사망.결론:PV시이혈전급출혈위주요병발증적골수증식성종류,기병은닉,혈청LDH여NSE수평고우정상치,추단혈청LDH여NSE수평가반영PV환자골수조혈세포적악성증식정도병가작위판정PV적료효지표지일.
The aim of this study was to analyse the clinical characteristics and laboratory data,treatment and prognosis of polycythemia vera (PV).A retrospective study was performed for 71 PV patients treated in our hospital during January 2001 to July 2011 including analysis of clinical characteristics,laboratory data,myelogram chronosome karyotypes,BCR/ABL and JAK2V617F genes,as well as lactate dehydrogenase(LDH) and neuron-specific enolase(NSE) levels in serum and so on.The results showed that 71 patients (37 males and 34 females with a average age of 57.8years) were diagnosed.Thrombosis and embolism occurred in 34 patients(47.89% ),hemorrhage in 10 patients ( 14.08% ),splenomegaly occurred in 44 patients.The onset of the disease was insidious,13 patients( 18.31% ) were found to have PV during the treatments for other diseases.The average hemoglobin at diagnosis was 206.31 ( 171 -242 )g/L.JAK2V617F mutation was detected in 31 (81.58%) of 38 patients studied.The average levels of serum LDH and NSE were higher than normal and both positively correlated with hemoglobin(P =0.007,P =0.005 ).The disease outcomes were myelofibrosis for 3 patients,death from cerebral hemorrhage for 1 patient,and death from ineffective chemotherapy in 1 patient with ANLL-M2.It is concluded that PV is a chronic myeloproliferative disorder characterized predominately by thrombosis and hemorrhage.The serum LDH and NSE levels are higher than the normal values.It is inferred that the serum LDH and NSE levels can reflect the degree of malignant proliferation of bone marrow hematopoietic cells and also can be used as an indicator to judge the therapeutic effect of PV.